<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): September 2, 2008</B>


<P style="font-size: 24pt" align="center"><B>TOMOTHERAPY
INCORPORATED<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Wisconsin</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>001-33452</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>39-1914727</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>1240 Deming Way<BR>
Madison,
Wisconsin<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>53717</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(608) 824-2800</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.</B>

<P style="font-size: 10pt" align="left">On August&nbsp;28, 2008, the Board of
Directors of TomoTherapy Incorporated (the &#8220;Company&#8221;)&nbsp;approved
the appointment of Roy T. Tanaka, age 60, as a director of the Company
effective September&nbsp;1, 2008. Mr.&nbsp;Tanaka brings to the
TomoTherapy Board 27&nbsp;years of
operational leadership experience, including global market expansion. He is newly retired
from Biosense Webster, Inc., a Johnson &amp; Johnson company, where he most
recently served as Worldwide President.

<P style="font-size: 10pt" align="left">Mr.&nbsp;Tanaka joined Johnson &amp;
Johnson in 1997 as the U.S. President of Biosense Webster, Inc. before being
named Worldwide President in 2004. From 1992 to 1997, he served in a variety of
senior management positions at Sorin Biomedical Inc., including President and
Chief Executive Officer. From 1989 to 1992, Mr.&nbsp;Tanaka served in Vice
President roles with Shiley, a division of Pfizer Incorporated. Mr.&nbsp;Tanaka
received a Bachelor of Science degree in Mechanical Engineering from Purdue
University and a Masters Degree in Business Administration from Illinois
Benedictine College.

<P style="font-size: 10pt" align="left">Mr.&nbsp;Tanaka replaces John P. Neis,
age 53, who retired from the Board of Directors of TomoTherapy effective
August&nbsp;31, 2008. Mr.&nbsp;Neis is the co-founder and Managing Director of
Venture Investors LLC, which participated in several rounds of venture capital
financing to TomoTherapy. There has been no disagreement with Mr.&nbsp;Neis as
to the Company&#8217;s policies, operations or practices.

<P style="font-size: 10pt" align="left">Mr.&nbsp;Neis served on the
Company&#8217;s Audit Committee, Compensation Committee, and Nominating and
Governance Committee. Effective September&nbsp;1, 2008, Mr.&nbsp;Tanaka was
appointed to the Audit Committee and Ms.&nbsp;Frances Taylor was appointed to
the Nominating and Governance Committee. Mr.&nbsp;John Greisch was previously
appointed to the Compensation Committee effective April&nbsp;1, 2008.

<P style="font-size: 10pt" align="left">On September&nbsp;2, 2008, Company
issued a press release entitled &#8220;TomoTherapy Incorporated Appoints Roy
Tanaka to Its Board of Directors.&#8221; A copy of the press release is
attached as Exhibit&nbsp;99.1 and incorporated herein by reference.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01. Financial Statements
and Exhibits.</B>

<P style="font-size: 10pt; text-indent: 3%" align="left">(d)&nbsp;Exhibits.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>Number</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Description</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated September&nbsp;2, 2008,
titled &#8220;TomoTherapy Incorporated Appoints Roy Tanaka to Its Board of
Directors&#8221;</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 2%"
align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="50%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="2%">&nbsp;</TD>
  <TD width="2%">&nbsp;</TD>
  <TD width="45%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD nowrap align="center"><B>&nbsp;</B></TD>
  <TD>&nbsp;</TD>
  <TD nowrap align="left"><B>TOMOTHERAPY INCORPORATED</B></TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD nowrap align="left">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD nowrap align="center"><B>&nbsp;</B></TD>
  <TD>&nbsp;</TD>
  <TD nowrap align="center"><B>&nbsp;</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">Dated: September&nbsp;2, 2008
</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">By: </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">/s/ Stephen C. Hathaway</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp; </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Stephen C. Hathaway<BR> <I>Chief Financial
Officer</I></TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>Number</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Description</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated September&nbsp;2, 2008,
titled &#8220;TomoTherapy Incorporated Appoints Roy Tanaka to Its Board of
Directors&#8221;</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c75028e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11572}]
{"company-data": {"conformed-name": "TomoTherapy Inc", "cik": "0001317872", "assigned-sic": "3845", "irs-number": "000000000"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33452", "film-number": "081051905"}, "business-address": {"street1": "1240 DEMING WAY", "city": "MADISON", "state": "WI", "zip": "53717-1954"}, "mail-address": {"street1": "1240 DEMING WAY", "city": "MADISON", "state": "WI", "zip": "53717-1954"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): September 2, 2008
TOMOTHERAPY
INCORPORATED
(Exact name of registrant as
specified in its charter)
Wisconsin
001-33452
39-1914727
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1240 Deming Way
Madison,
Wisconsin
53717
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(608) 824-2800
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On August 28, 2008, the Board of
Directors of TomoTherapy Incorporated (the "Company") approved
the appointment of Roy T. Tanaka, age 60, as a director of the Company
effective September 1, 2008. Mr. Tanaka brings to the
TomoTherapy Board 27 years of
operational leadership experience, including global market expansion. He is newly retired
from Biosense Webster, Inc., a Johnson & Johnson company, where he most
recently served as Worldwide President.
Mr. Tanaka joined Johnson &
Johnson in 1997 as the U.S. President of Biosense Webster, Inc. before being
named Worldwide President in 2004. From 1992 to 1997, he served in a variety of
senior management positions at Sorin Biomedical Inc., including President and
Chief Executive Officer. From 1989 to 1992, Mr. Tanaka served in Vice
President roles with Shiley, a division of Pfizer Incorporated. Mr. Tanaka
received a Bachelor of Science degree in Mechanical Engineering from Purdue
University and a Masters Degree in Business Administration from Illinois
Benedictine College.
Mr. Tanaka replaces John P. Neis,
age 53, who retired from the Board of Directors of TomoTherapy effective
August 31, 2008. Mr. Neis is the co-founder and Managing Director of
Venture Investors LLC, which participated in several rounds of venture capital
financing to TomoTherapy. There has been no disagreement with Mr. Neis as
to the Company's policies, operations or practices.
Mr. Neis served on the
Company's Audit Committee, Compensation Committee, and Nominating and
Governance Committee. Effective September 1, 2008, Mr. Tanaka was
appointed to the Audit Committee and Ms. Frances Taylor was appointed to
the Nominating and Governance Committee. Mr. John Greisch was previously
appointed to the Compensation Committee effective April 1, 2008.
On September 2, 2008, Company
issued a press release entitled "TomoTherapy Incorporated Appoints Roy
Tanaka to Its Board of Directors." A copy of the press release is
attached as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits.
Number
Description
99.1
Press Release dated September 2, 2008,
titled "TomoTherapy Incorporated Appoints Roy Tanaka to Its Board of
Directors"
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
TOMOTHERAPY INCORPORATED
Dated: September 2, 2008
By:
/s/ Stephen C. Hathaway
Stephen C. Hathaway
Chief Financial
Officer
EXHIBIT INDEX
Number
Description
99.1
Press Release dated September 2, 2008,
titled "TomoTherapy Incorporated Appoints Roy Tanaka to Its Board of
Directors"